Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney and thyroid cancers using its investigational therapy LP-184 (zirdafulven) based on a three-gene biomarker signature. The allowed claims cover the use of elevated expression of PTGR1, PTPN14 and ASPH to identify patients who may benefit from treatment with LP-184.
The company said its RADR(R) artificial intelligence platform helped identify the biomarker signature used in the patent, supporting the development of a precision medicine approach for LP-184. Lantern reported a 45% disease control rate among patients treated at or above the effective therapeutic dose in its Phase 1a trial and plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio. For more details, see the full press release at https://ibn.fm/LRGUo.
This patent allowance strengthens Lantern's position in precision oncology by enabling targeted patient selection for LP-184, potentially improving treatment outcomes and reducing side effects. The biomarker signature, discovered via RADR(R), exemplifies how artificial intelligence can accelerate drug development and identify responsive patient populations. Lantern's Phase 1a data showing a 45% disease control rate at effective doses underscores the therapy's promise.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI and its proprietary RADR(R) platform to transform cancer therapy development. Its pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound), and LP-300, which is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned subsidiary. Additionally, the company's withZeta.ai platform is commercially available as a subscription-based research tool. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. For the latest updates, visit the company's newsroom at https://ibn.fm/LTRN.
The patent allowance marks a key milestone for Lantern as it prepares to initiate Phase 1b/2 studies in 2026, potentially expanding therapeutic options for hard-to-treat cancers. The use of a multi-gene biomarker aligns with the industry's shift toward precision medicine, where treatments are tailored to genetic profiles. This approach could differentiate LP-184 from conventional chemotherapies and improve clinical outcomes.
